Actin-related protein 2/3 complex subunit 1B promotes cervical cancer cell tumorigenesis in vitro and in vivo.

IF 3.1 3区 医学 Q2 ONCOLOGY
American journal of cancer research Pub Date : 2026-07-15 eCollection Date: 2026-01-01 DOI:10.62347/XCGE7946
Xin Jin, Qiyue Zhang, Xinru Ling, Yanbo Liu, Tiantian Wu, Guannan Feng
{"title":"Actin-related protein 2/3 complex subunit 1B promotes cervical cancer cell tumorigenesis in vitro and in vivo.","authors":"Xin Jin, Qiyue Zhang, Xinru Ling, Yanbo Liu, Tiantian Wu, Guannan Feng","doi":"10.62347/XCGE7946","DOIUrl":null,"url":null,"abstract":"<p><p>Cervical cancer (CC) is a major cause of cancer-related mortality in women, with limited therapeutic options for advanced-stage disease. Although Actin-related protein 2/3 complex subunit 1B (ARPC1B) has been shown to play a role in multiple tumours, it is not yet well understood in cervical cancer. Our study has demonstrated that ARPC1B is an important contributor in CC progression. Bioinformatic analysis and tissue microarray (TMA) results revealed that ARPC1B is much more expressed in human cervical carcinoma tissues and positively correlates with poor prognosis. Through a series of in vitro and in vivo functional assays, we showed that ARPC1B plays a decisive role in the proliferation, migration and invasion of cervical cancer cells. Specifically, ARPC1B knockout suppresses the aforementioned malignant phenotypes, whereas its overexpression enhances them. We also proved that ARPC1B promotes tumorigenesis in xenograft models. These findings collectively establish ARPC1B as a novel oncogene in cervical cancer, indicating its potential role as both a biological prognostic marker and a therapeutic target for patients with cervical cancer.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 7","pages":"2955-2970"},"PeriodicalIF":3.1000,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13468235/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/XCGE7946","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cervical cancer (CC) is a major cause of cancer-related mortality in women, with limited therapeutic options for advanced-stage disease. Although Actin-related protein 2/3 complex subunit 1B (ARPC1B) has been shown to play a role in multiple tumours, it is not yet well understood in cervical cancer. Our study has demonstrated that ARPC1B is an important contributor in CC progression. Bioinformatic analysis and tissue microarray (TMA) results revealed that ARPC1B is much more expressed in human cervical carcinoma tissues and positively correlates with poor prognosis. Through a series of in vitro and in vivo functional assays, we showed that ARPC1B plays a decisive role in the proliferation, migration and invasion of cervical cancer cells. Specifically, ARPC1B knockout suppresses the aforementioned malignant phenotypes, whereas its overexpression enhances them. We also proved that ARPC1B promotes tumorigenesis in xenograft models. These findings collectively establish ARPC1B as a novel oncogene in cervical cancer, indicating its potential role as both a biological prognostic marker and a therapeutic target for patients with cervical cancer.

肌动蛋白相关蛋白2/3复合物亚基1B在体外和体内促进宫颈癌细胞的肿瘤发生。
宫颈癌(CC)是妇女癌症相关死亡的主要原因,对晚期疾病的治疗选择有限。虽然肌动蛋白相关蛋白2/3复合物亚基1B (ARPC1B)已被证明在多种肿瘤中发挥作用,但在宫颈癌中尚未得到很好的了解。我们的研究表明,ARPC1B是CC进展的重要贡献者。生物信息学分析和组织微阵列(TMA)结果显示,ARPC1B在人宫颈癌组织中表达量显著增加,且与预后不良呈正相关。通过一系列体外和体内功能实验,我们发现ARPC1B在宫颈癌细胞的增殖、迁移和侵袭中起决定性作用。具体来说,ARPC1B敲除抑制了上述恶性表型,而其过表达则增强了这些表型。我们还证明了ARPC1B促进异种移植模型中的肿瘤发生。这些发现共同确立了ARPC1B在宫颈癌中的新致癌基因地位,表明其作为宫颈癌患者生物学预后标志物和治疗靶点的潜在作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
3.80%
发文量
263
期刊介绍: The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书